Advertisement

Search Results

Advertisement



Your search for Alice Goodman matches 1552 pages

Showing 1 - 50


gynecologic cancers

Expert Point of View: Ernst Lengyel, MD, PhD

Invited discussant Ernst Lengyel, MD, PhD, of University of Chicago Medicine, found the results of ATHENA-MONO promising. “I think it is encouraging that in the BRCA-mutation subgroup of patients, we see such a clear increase in progression-free survival compared to the intention-to-treat...

gynecologic cancers

Rucaparib Maintenance Improves Progression-Free Survival in Patients With Newly Diagnosed Advanced Ovarian Cancer Who Responded to Platinum-Based Therapy

Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib led to a significant improvement in progression-free survival compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy. The...

Expert Point of View: Ben Creelan, MD

Ben Creelan, MD, Associate Member of Moffitt Cancer Center, Tampa, Florida, provided some context for the CHRYSALIS study. “This dual bispecific antibody targeting both EGFR and MET clearly has potent single-agent activity in patients with MET exon 14 skipping NSCLC,” he said. “For now, it is not...

lung cancer

Chipping Away at Targetable Mutations in NSCLC: Amivantamab in NSCLC With MET Exon 14 Skipping Mutations

Dual targeting with the bispecific antibody amivantamab-vmjw showed antitumor activity and tolerability in patients with metastatic non–small cell lung cancer (NSCLC) and MET exon 14 skipping mutations, according to results of the ongoing phase I CHRYSALIS study.1,2 Updated results were presented...

breast cancer
immunotherapy

Expert Point of View: Patricia LoRusso, DO, PhD

Invited discussant Patricia LoRusso, DO, PhD, of Yale School of Medicine, said to the assembled audience at the 2022 ASCO Annual Meeting: “I see you are as excited about these data as I am,” after the applause ended following Dr. Modi’s presentation. “I want to thank our colleagues for helping to...

breast cancer
immunotherapy

DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...

Jeremy Abramson, MD, Comments on Results From the SHINE Trial

Jeremy Abramson, MD, Director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, was enthusiastic about these data. “These important data show that ibrutinib added to bendamustine/rituximab ...

lymphoma

Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma

Primary results from the phase III SHINE trial demonstrated that first-line treatment with ibrutinib combined with bendamustine/rituximab and rituximab maintenance achieves a substantial prolongation of progression-free survival in elderly patients with mantle cell lymphoma, according to a...

lung cancer
immunotherapy

Expert Point of View: David Paul Carbone, MD, PhD

“Progress in lung cancer happens by slow steps punctuated by quantum leaps. In the age of perioperative therapies, we are moving one step closer to curing more patients. Surgery is still the intervention most likely to cure patients with earlier-stage disease, but 50% of cases can recur,” said...

lung cancer
immunotherapy

CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy Improves Event-Free Survival Over Chemotherapy Alone in Resectable NSCLC

The combination of neoadjuvant nivolu­mab plus chemotherapy achieved statistically significant and clinically meaningful improvement in event-free survival vs chemotherapy alone (P = .005) in patients with resectable non–small cell lung cancer (NSCLC, stage IB–IIIA), according to the results of the ...

lung cancer
immunotherapy

Expert Point of View: Edward B. Garon, MD

Invited discussant of the NeoCOAST trial, Edward B. Garon, MD, Professor of Medicine and Director of the Thoracic Oncology Program at David Geffen School of Medicine at the University of California Los Angeles, praised the study: “NeoCOAST is an impressive study that showed numerical benefit when...

lung cancer
immunotherapy

Novel Neoadjuvant Therapy May Boost Response in Resectable NSCLC

Use of multiple immune pathway inhibitors appears to be superior to checkpoint inhibitor therapy alone as neoadjuvant therapy for resectable non–small cell lung cancer (NSCLC), according to the results of the phase II NeoCOAST trial presented at the American Association for Cancer Research (AACR)...

gynecologic cancers

Combination Therapy of Olaparib, Cyclophosphamide, and Metformin Under Study in Advanced Endometrial Cancer

A triplet regimen consisting of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib, metronomic (the chronic administration of low, equally spaced doses of) cyclophosphamide, and metformin demonstrated activity in elderly, heavily pretreated patients with recurrent, advanced endometrial...

skin cancer
immunotherapy

Mario Sznol, MD, and Stefania Scala, MD, on Improving Responses to Immunotherapy in Patients With Melanoma

Invited study discussant of the use of ipilimumab plus nivolumab in resistant melanoma, at the AACR Annual Meeting 2022, Mario Sznol, MD, of Yale University Cancer Center, indicated that the substantial increase in progression-free survival at 6 months was not maintained. “The durable...

skin cancer
immunotherapy

Approaches to Potentiate Immune Response in Patients Who Do Not Respond to Anti–PD-1 Therapy for Melanoma

A sizable proportion of patients with advanced melanoma will experience disease progression on anti–PD-1 therapy, and the optimal treatment of such patients represents an unmet need. Two studies presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 explored separate...

covid-19

CoVac-1 Vaccination Studied for Prevention of Severe COVID-19 in Immune-Deficient Patients With Cancer

CoVac-1, a multipeptide COVID-19 vaccine candidate, elicited immunogenicity in patients with cancer and disease-related or treatment-related immunoglobulin deficiency in a phase I/II trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 These patients are...

solid tumors
genomics/genetics

Next-Generation PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors

The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305 suggests this drug may be a welcome advance over its U.S. Food and Drug Administration (FDA)-approved predecessors in the treatment of solid tumors with alterations in...

prostate cancer

Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer

The use of a polygenic score incorporating variations in prostate-specific antigen (PSA) values that are not due to cancer may allow for more precise PSA screening, according to findings of a large genome-wide association study presented at the American Association for Cancer Research (AACR) Annual ...

Expert Point of View: Julio Chavez, MD and Hayder Saeed, MD

Julio Chavez, MD, of the Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, was cautiously enthusiastic about these findings in CD30-positive lymphoma. “This clinical trial is novel, as it engages cord blood derived-NK cells to attack CD30-positive tumor cells using a...

lymphoma
immunotherapy

Natural Killer Cells Precomplexed With Innate Cell Engager Show Activity in CD30-Positive Lymphoma

Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89%, with 53% complete...

Expert Point of View: Mark Awad, MD, PhD

“In the past decade, major improvements in treating lung cancer have come from identification of mutations and development of drugs to target those mutations: EGFR, ALK, RET, HER2, and others. Finally, we can add KRAS as a druggable target,” stated invited discussant Mark Awad, MD, PhD, Clinical...

lung cancer

2-Year Follow-up Shows Durable Responses With Sotorasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer

Sotorasib, the first KRAS G12C inhibitor approved for the treatment of KRAS G12C–mutated non–small cell lung cancer (NSCLC), continues to demonstrate meaningful and durable efficacy at 2-year follow-up in the phase II CodeBreaK 100 trial. At a median follow-up of 24.9 months, the 2-year overall...

Expert Point of View: Jane N. Winter, MD

Jane N. Winter, MD, moderator of the press conference on late-breaking abstracts at the 2021 American Society of Hematology (ASH) Annual Meeting & Exhibition, commented on the BELINDA study in the context of two investigations that had been previously reported at the same meeting, showing...

lymphoma
immunotherapy

BELINDA Trial: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma

The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to results of the phase III BELINDA trial,...

Expert Point of View: Laurie H. Sehn, MD, MPH

Press conference moderator, Laurie H. Sehn, MD, MPH, of the University of British Columbia, Vancouver, Canada, noted, that her center participated in the single-arm trial of mosunetuzumab. “We witnessed first-hand the tremendous capacity bispecific antibodies have to make a real difference in...

lymphoma

Mosunetuzumab Meets Primary Endpoint of Phase II Trial in Relapsed or Refractory Follicular Lymphoma

The bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy in patients with relapsed or refractory follicular lymphoma, according to the results of a pivotal phase II trial presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In ...

Expert Point of View: Susan M. O’Brien, MD

The GAIA trial raises some important points, according to Susan M. O’Brien, MD, Associate Director for Clinical Research at the UCI Chao Family Comprehensive Cancer Center in Irvine, California. Dr. O’Brien co-moderated the session where Dr. Eichhorst presented study results. “The CLL14 trial...

leukemia

Improved Outcomes With Time-Limited Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL

Administering time-limitedcombination regimens of venetoclax plus obinutuzumab or venetoclax plus obinutuzumab and ibrutinib was superior to chemoimmunotherapy in achieving undetectable measurable residual disease (MRD) in the peripheral blood at month 15 in fit patients with chronic lymphocytic...

leukemia

Expert Point of View: Joshua Brody, MD

Joshua Brody, MD, Director of the CLL/Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, New York, who was not involved in these trials, commented: “CLL is an extremely prevalent disease affecting nearly 200,000 patients in the United States. Most patient do not require...

leukemia

Fixed-Duration Venetoclax Plus Ibrutinib Achieves Deep and Durable MRD Remissions in CLL

Two different trials presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition found that fixed-duration treatment with ibrutinib and venetoclax achieved deep and sustained undetectable measurable residual disease (MRD) status when used as first-line therapy for...

Expert Point of View: Jacqueline C. Barrientos, MD, MS

Invited study discussant Jacqueline C. Barrientos, MD, MS, of Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, commented: “The BTK [Bruton’s tyrosine kinase] inhibitors ibrutinib and acalabrutinib, along with the BCL2 inhibitor venetoclax, are ...

leukemia

ELEVATE-RR Trial: Acalabrutinib as Effective as Ibrutinib, With Fewer Cardiac Effects, in Resistant CLL

Acalabrutinib was equally efficacious with less toxicity when compared directly with ibrutinib in patients with previously treated relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of an open-label, randomized, noninferiority phase III trial presented at the 2021...

Expert Point of View: Aditya Bardia, MD, MPH

Aditya Bardia, MD, MPH, Director of Breast Cancer Research and Attending Physician at Massachusetts General Hospital, and Associate Professor at Harvard Medical School, commented on this study on recurrence of ductal carcinoma in situ (DCIS). “This is an interesting study that evaluated whether...

breast cancer

Some Recurrences of Ductal Carcinoma In Situ May Be Genetically Distinct From the Primary Tumor, Study Reports

Contrary to what has been assumed, all recurrences of ductal carcinoma in situ (DCIS) are not genetically the same, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 Almost 20% of ipsilateral recurrences found in the study were genetically...

leukemia

Study Examines Disparities in Relapse Among Pediatric Patients With ALL

According to a large multiethnic study presented by Sok et al at the American Association for Cancer Research (AACR) Annual Meeting 2022, Latinx children with acute lymphoblastic leukemia (ALL) and measurable residual disease (MRD)-negative status were more likely to relapse compared with...

lymphoma

Novel Approach Using Off-the-Shelf Preactivated NK Cells Shows Efficacy in CD-30 Positive Lymphoma

Natural killer (NK) cells derived from donated umbilical cord blood and activated with a novel bispecific antibody known as AFM13 (which targets CD16A and CD30) were shown to be effective in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89% in...

lung cancer

Sotorasib Achieves Durable Responses in KRAS G12C–Mutated Lung Cancer

Sotorasib, the first KRAS G12C inhibitor approved for the treatment of KRAS G12C–mutated non–small cell lung cancer (NSCLC), continues to demonstrate meaningful and durable efficacy at 2-year follow-up in the phase II CodeBreaK 100 trial. At a median follow-up of 15.3 months, 2-year overall...

bladder cancer
immunotherapy

Expert Point of View: Guru P. Sonpavde, MD

Guru P. Sonpavde, MD, Director of the Bladder Cancer Program at Dana-Farber Cancer Institute, Boston, said the therapeutic landscape of urothelial cancer has been altered by PD-L1 inhibitors and antibody-drug conjugates. “The rationale for Cohort 3 was based on high response rates seen with a...

bladder cancer
immunotherapy

Second-Line Combination Study in Urothelial Cancer

The combination of the antibody-drug conjugate sacituzumab govitecan-hziy and the immune checkpoint inhibitor pembrolizumab yielded antitumor activity as second-line therapy in patients with platinum-refractory, checkpoint inhibitor–naive, metastatic urothelial cancer, according to the results of...

Expert Point of View: Sandy Srinivas, MD

“Prior to these two studies, smaller studies showed a lack of response to PARP [poly (ADP-ribose) polymerase] inhibitors in previously treated patients with urothelial cancer, both as monotherapy and in combinations,” said formal discussant of the BAYOU and ATLANTIS trials, Sandy Srinivas, MD,...

bladder cancer

Trials of PARP Inhibitors in Urothelial Cancer: More Questions Than Answers?

Two studies presented at the 2022 ASCO Genitourinary Cancers Symposium explored the role of poly (ADP-ribose) polymerase (PARP) inhibitors in urothelial cancer: ATLANTIS and BAYOU.1,2 Results suggest that PARP inhibitors may be useful in certain genetic subgroups and perhaps in combination with...

kidney cancer
immunotherapy

Several Studies Evaluate Agents in the First-Line, Second-Line, and Later Treatment of Advanced Kidney Cancer

The combination of nivolumab plus cabozantinib achieved a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma, according to a final overall survival analysis of the phase III CheckMate 9ER trial.1 Additionally,...

Expert Point of View: Hao G. Nguyen, MD, PhD

Invited discussant Hao G. Nguyen, MD, PhD, of the University of California, San Francisco, said: “New treatments are needed for advanced penile cancer. PERICLES is the first randomized trial for patients with stage IV penile cancer treated without chemotherapy. Although this prospective trial...

immunotherapy

Atezolizumab Induces Responses in Advanced Penile Cancer, but Biomarkers Needed to Improve Patient Selection

Use of the immune checkpoint inhibitor atezolizumab with or without radiotherapy showed antitumor activity in stage IV penile cancer in the phase II PERICLES trial, although the study failed to meet the primary endpoint of 1-year progression-free survival of at least 35%. The hints of activity were ...

Expert Point of View: Xin Gao, MD

Xin Gao, MD, of Harvard Medical School and Massachusetts General Hospital Cancer Center, commented on this study: “ARIES is a phase II study evaluating the anti–PD-L1 therapy avelumab in cisplatin-ineligible advanced urothelial cancer patients with a PD-L1 expression of at least 5% on tumor cells...

immunotherapy

ARIES Trial: Avelumab Failed to Improve 1-Year Survival in PD-L1–Positive Advanced Urothelial Cancer

First-line treatment with the PD-L1 antibody avelumab failed to meet the primary endpoint of an improvement in overall survival at 1 year for patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer. However, the objective response and disease control rates were favorable in...

Expert Point of View: Daniel M. Geynisman, MD

Invited discussant Daniel M. Geynisman, MD, of Fox Chase Cancer Center, Philadelphia, found the longer-term follow-up of KEYNOTE-564 “reassuring.” Dr. Geynisman continued: “Following nephrectomy, the goal of adjuvant treatment is to ideally cure or at least significantly delay disease progression. ...

kidney cancer
immunotherapy

KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma

An updated analysis of the phase III KEYNOTE-564 trial continues to support the use of adjuvant pembrolizumab vs placebo in patients with renal cell carcinoma at high risk of recurrence, according to a presentation at the 2022 ASCO Genitourinary Cancers Symposium.1 At 30 months of follow-up,...

prostate cancer

Expert Point of View: Elisabeth I. Heath, MD, FACP, and Oliver Sartor, MD

Formal discussant of the ARASENS trial, Elisabeth I. Heath, MD, FACP, Professor of Oncology and Associate Center Director, Translational Sciences, at Karmanos Cancer Institute in Detroit, commented on the changing paradigm in prostate cancer treatment. “The narrative is changing to triplet therapy, ...

Expert Point of View: Guru P. Sonpavde, MD

Invited discussant Guru P. Sonpavde, MD, Director of the Bladder Cancer Program at Dana-Farber Cancer Institute, said: “Antibody-drug conjugates are a major weapon in the way forward in bladder cancer…. The EV-103 trial evaluated neoadjuvant therapy with enfortumab vedotin-ejfv, one of two...

Advertisement

Advertisement



Advertisement